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ABSTRACT 
We report herein a detailed study concerning the impact of different bioconjugation and 
nanoformulation strategies on the in vitro targeting ability of peptide-decorated squalenoyl 
gemcitabine (SQdFdC) nanoparticles (NPs). NPs have been functionalized with the CKAAKN 
peptide, previously identified as efficient homing device within the pancreatic pathological 
microenvironment. Two approaches have been followed: (i) either the CKAAKN peptide was 
directly conjugated at the surface of preformed SQdFdC nanoparticles (conjugation after NP 
formation) or (ii) it was first reacted with a maleimide squalenoyl derivative before the resulting 
bioconjugate was co-nanoprecipitated with SQdFdC to form the peptide-decorated NPs 
(conjugation before NP formation). NPs were characterized with respect to mean diameter, zeta 
potential and stability over time. Then, their specific interaction with the sFRP-4 protein was 
evaluated by surface plasmon resonance. Although both the synthetic strategies allowed to 
formulate NPs able to interact with the corresponding receptor, enhanced target binding and 
better specific avidity were observed with CKAAKN-NPs functionalized before NP formation. 
These NPs displayed the highest cell uptake and cytotoxicity in an in vitro model of human 
MIA Paca-2 pancreatic cancer cells.  
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INTRODUCTION 
The ability to selectively deliver drugs to tumor cells with minimal interaction with healthy 
tissues is a major challenge in chemotherapy. To this aim, suitable ligands able to bind to 
specific receptors, overexpressed on cancer cells and relatively downregulated on healthy 
tissues, have been successfully employed as a valuable strategy to specifically target tumors.1 
By means of molecular recognition, such targeted therapy has improved the balance between 
efficacy and toxicity of conventional systemic anticancer treatments2 , 3 as observed, for 
instance, in the case of antibody-conjugated chemotherapeutic agents.3-5 Several antibody-drug 
conjugates are currently included in clinical trials with encouraging results6 and two examples, 
Adcetris® (Takeda, Seattle Genetics) and Kadcyla® (Roche, Genentech), have recently been 
approved by FDA and EMA.7-8 
In parallel, the use of targeting ligands grafted to the surface of nanoscale drug delivery devices 
(i.e., nanomedicines) appears as another promising approach.9 Compared to molecular 
conjugates, nanocarriers offer the advantage to protect the drug molecule from degradation and 
to better control drug release. Moreover, by tuning the number of ligand molecules onto the 
nanocarrier surface, targeting efficacy might be improved via a multivalent binding process.10 
In the past 30 years, a plethora of targeted nanoparticles functionalized with various ligands 
belonging to the families of small molecules, polysaccharides, peptides, proteins or even 
antibodies has been developed.11-12 Nanomedicines are gaining more and more attention in 
cancer therapy13-14 with 5 examples on the market and 10 in clinical development.15 
However, not any ligand-decorated nanomedicine has reached the market and only 5 are 
currently in early clinical trials.15-16 
Several functionalization strategies and coupling methods have been developed, each of them 
exhibiting benefits and drawbacks (for systematic review see 11). In general, the targeting 
efficacy of a functionalized nanocarrier is governed by (i) the nature of the matrix and the 
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ligand, (ii) the selected coupling reaction, (iii) the disposition of the ligand at the surface and 
(iv) the ligand surface density.17-22 Two main ligation strategies have been used to display the 
targeting agents at the surface of the nanocarriers: the ligand can either (i) be directly coupled 
in aqueous solution to the surface of preformed nanocarriers or (ii) be linked to the nanocarrier 
components prior to nanocarrier construction (Figure 1a). 
The first strategy is generally preferred because the ligand is directly grafted onto the 
nanoparticle surface and available for the receptor recognition, whereas the linkage of bulky 
ligands (such as polypeptides, proteins or antibodies) to the nanocarrier building material might 
alter its hydrophilic/lipophilic balance and its self-assembly properties.11 An undeniable 
advantage of the second strategy relies on the possibility to control the reaction yield, to purify 
and characterize the resulting conjugate. However, the solubilization in organic solvents, that 
is sometimes required, could cause denaturation of the proteins or antibodies compromising 
their affinity for the receptor. In addition, in this approach the ligand is susceptible of 
entrapment into the nanocarrier core during nanoparticle preparation, leading to insufficient 
surface coverage and lower availability for interaction with the corresponding receptor. 
Therefore, a comparative study about advantages/disadvantages of each strategy should be done 
for any new system, in order to achieve successful actively targeted nanoparticles. 
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Figure 1. a) Strategies to prepare ligand-functionalized NPs: (i) the ligand can be coupled to 
the surface after nanoparticle formation or (ii) be directly conjugated to the nanocarrier building 
material prior to NP formation. b) Schematic representation of possible ligand disposition after 
both ligation strategies. Blue titles are referred to (i) ligand coupling after nanoparticle 
preparation and violet ones to (ii) ligand coupling before nanoparticle preparation. The green 
segment symbolizes the successful ligand coating, while yellow and red ones correspond to low 
and inefficient ligand disposition, respectively. 
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In this study, we report a rational approach for the design of ligand-targeted squalene-based 
nanoparticles for specific drug delivery to pancreatic tumor cells. The “squalenoylation” 
approach consists in the chemical linkage of squalene (SQ), a natural triterpene precursor in the 
sterol biosynthesis, to biologically active molecules. The obtained lipid bioconjugates are able 
to self-assemble in aqueous solution to form stable nanoparticles with high drug payloads.23 
Such innovative concept has firs been applied to gemcitabine (dFdC), which is the first-line 
therapeutic agent in pancreatic cancer treatment.24 After intravenous administration, 4-(N)-
trisnorsqualenoylgemcitabine (SQdFdC) nanoparticles exhibited impressively greater 
anticancer activity than the free drug against different tumor models (e.g., experimental 
leukemia and pancreatic cancer).23, 25-27 However, the physio-pathological complexity of 
pancreatic cancer28 urgently required the development of better targeted therapeutic approaches 
to enhance selective nanoparticle internalization by cancer cells, also avoiding potential side 
effects.  
In this context, functionalized SQdFdC nanoparticles were prepared by linking the CKAAKN 
peptide, previously identified as efficient homing device within the pancreatic pathological 
microenvironment by phage display screening.29 These nanoparticles were found to be more 
efficient than non CKAAKN-functionalized nanoparticles on a transgenic mice model of 
pancreatic cancer.30 Herein, we performed a comparative study to establish the optimal 
CKAAKN peptide-SQdFdC nanoparticle ligation strategy. Briefly, CKAAKN peptide was 
conjugated to the nanoparticles by the well-explored thiol-maleimide Michael addition 
coupling strategy either (i) by reacting the targeting moiety with preformed nanoparticles 
obtained in accordance with the nanoprecipitation technique (Figure 1a – left panel) or (ii) by 
conjugating the peptide with a squalenoyl derivative before constructing nanoparticles by 
mixing the obtained bioconjugate with SQdFdC (Figure 1a – right panel). The resulting 
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CKAAKN-SQdFdC nanoparticles were characterized with respect to size, zeta potential, 
stability, receptor binding affinity and in vitro targeting ability. 
 
 
RESULTS AND DISCUSSION 
 Preparation and characterization of non targeted nanoparticles. In order to obtain 
stable CKAAKN-functionalized SQdFdC nanoparticles, the formulation of the colloidal system 
was deeply investigated by tuning the preparation conditions. In particular, a maleimide group-
bearing squalene derivative (SQMal) able to link the peptide via its thiol function was added to 
SQdFdC (1) in various molar ratios. Moreover, two different spacers were introduced between 
the squalene moiety and the maleimide group. In the case of the SQMallipo (3),30 a 6-carbon 
atom lipophilic chain served as a spacer, while for the SQMalhydro (4),31 a hydrophilic ether 
chain was inserted (Figure 2). 
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Figure 2. Structures of SQdFdC (1), CKAAKN peptide (2), SQMallipo (3), SQMalhydro (4) and 
SQCKAAKN (5).  
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All NPs were prepared by nanoprecipitation, using acetone or ethanol as organic solvent and 
without adding any surfactant. Maleimide-bearing SQdFdC NPs were prepared by adding 
SQMallipo or SQMalhydro.  
SQdFdC and SQMallipo were co-nanoprecipitated at various SQdFdC/SQMallipo molar ratios 
(10:1, 5:1, 2:1) with a constant SQdFdC concentration (either in acetone or in ethanol), giving 
a suspension of narrow monodispersed NPs (N1). Addition of SQMallipo led to a slight size 
increase compared to SQdFdC NPs which displayed a mean diameter of 141 nm and 122 nm 
when prepared in acetone (N0a) or ethanol (N0e), respectively (Table 1).  
SQdFdC/SQMalhydro NPs (N2) were prepared by co-nanoprecipitation of SQdFdC and 
SQMalhydro at two molar ratios (10:1, 5:1), with a constant SQdFdC concentration. Ethanol 
turned out to be the best solvent, while when acetone was employed NPs instantly aggregated. 
As observed for SQdFdC/SQMallipo, N2e displayed a mean diameter of less than 200 nm and a 
narrow particle size distribution (Table 1). However, the presence of an ether chain between 
the maleimide group and the squalene moiety affected the nanoparticle stability, probably due 
to a modification of the internal inverted hexagonal phase structure of SQdFdC nanoparticles.32 
On the contrary, a higher stability was observed when a lipophilic chain was used as spacer 
(SQMallipo).  
According to these results, the SQMallipo was preferred to the SQMalhydro for the preparation of 
peptide-targeted SQdFdC nanoparticles. Acetone was selected as solvent due to the higher 
colloidal stability of N1a nanoparticles compared to those prepared in ethanol (N1e). Using 
acetone as solvent and a low or medium amount of SQMallipo (SQdFdC/SQMallipo 10:1 or 5:1), 
no precipitation was detected after 1-week storage at 4°C.  
 
10 
 
Table 1. Nanoparticle composition and characterization. 
NPs 
Solvent used in the 
nanoprecipitation 
Composition 
Components molar 
ratio 
Mean 
diameter  
(nm ± S.D.) 
Polydispersity 
index 
Zeta potential 
(mV ± S.D.) 
Stability 
at 4 °C 
(days) 
N0a Acetone SQdFdC - 141 ± 42 0.087 -22 ± 4 3 
N0e Ethanol SQdFdC - 122 ± 8 0.103 -22 ± 5 3 
N1a Acetone SQdFdC/SQMallipo 10:1 164 ± 42 0.066 -27 ± 3 7 
 Acetone SQdFdC/SQMallipo 5:1 171 ± 41 0.057 -29 ± 3 7 
 Acetone SQdFdC/SQMallipo 2:1 182 ± 20 0.047 -36 ± 3 3 
N1a-P Acetone 
SQdFdC/SQMallipo/ 
CKAAKN 
10:1:0.5 281 ± 10 0.134 -15 ± 1 < 3 
 Acetone 
SQdFdC/SQMallipo/ 
CKAAKN 
10:1:0.25 187 ± 7 0.067 -11 ± 1 < 3 
 Acetone 
SQdFdC/SQMallipo/ 
CKAAKN 
5:1:0.5 Aggregation / / / 
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N1a-P* Acetone 
SQdFdC/SQMallipo/ 
CKAAKN 
5:1:0.25 245 ± 16 0.141 -10 ± 2 3 
N1e Ethanol SQdFdC/SQMallipo 10:1 132 ± 9 0.100 -22 ± 7 3 
 Ethanol SQdFdC/SQMallipo 5:1 167 ± 9 0.053 -22 ± 3 3 
 Ethanol SQdFdC/SQMallipo 2:1 Aggregation / / / 
N2a Acetone SQdFdC/SQMalhydro 10:1 Aggregation / / / 
 Acetone SQdFdC/SQMalhydro 5:1 Aggregation / / / 
N2e Ethanol SQdFdC/SQMalhydro 10:1 183 ± 5 0.055 -16 ± 1 < 3 
 Ethanol SQdFdC/SQMalhydro 5:1 177 ± 3 0.053 -25 ± 3 < 3 
N3 Acetone 
SQMallipo 
0.5 mg/mL 
- 600 ± 180 0.091 -56.57 ± 3 7 
 Acetone 
SQMallipo 
1 mg/mL 
- 387 ± 101 0.068 -38.47 ± 3 7 
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a NPs formulated using acetone as solvent  
e NPs formulated using ethanol as solvent 
* Formulations chosen for Surface Plasmon Resonance analysis and in vitro studies 
 Acetone 
SQMallipo 
2 mg/mL 
- 436 ± 148 0.099 -49.81 ± 4 7 
N4-P Ethanol SQdFdC/SQCKAAKN 1:0.1 186 ± 104 0.032 11 ± 2 < 3 
 Ethanol SQdFdC/SQCKAAKN 1:0.05 897 ± 11 0.332 7 ± 23 < 3 
N4-P* Ethanol SQdFdC/SQCKAAKN 1:0.01 168 ± 16 0.117 -6 ± 5 3 
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SQMallipo alone was able to spontaneously self-assemble in water forming nanoparticles (N3) 
which, however, displayed a large mean diameter (400-600 nm) (Table 1). 
Compared to SQdFdC NPs (N0) or SQMallipo NPs (N3), mixed SQdFdC/SQMallipo NPs 
showed an intermediate mean diameter with higher colloidal stability, suggesting that the co-
nanoprecipitation technique allowed an efficient incorporation of SQMallipo in the resulting 
composite nanoparticles probably due to the capacity of the squalene chain to insert into the 
nanoparticle core. SQMallipo NPs (N3) showed zeta potential values ranging from around -30 
to -60 mV. Accordingly, the zeta potential value of N1a (SQdFdC/SQMallipo NPs prepared 
using acetone) gradually decreased (from around -20 to -40 mV) with the increase of SQMallipo 
in the formulation (Table 1). On the other hand, when ethanol was used as solvent (N1e), the 
amount of SQMallipo did not influence the zeta potential, suggesting that this experimental 
setting not only led to less stable NPs, but probably also did not allow the right exposition of 
the maleimide groups. Although for pure SQdFdC NPs the choice of the solvent did not 
influence the colloidal characteristics23, 33-34, these results were in concordance with other 
experiments that highlighted the crucial role of the solvent in the nanoparticle self-
organization35-38; they also supported the choice of using only the acetone-formulated 
SQdFdC/SQMallipo NPs for further investigations. 
 
 Preparation and characterization of targeted nanoparticles by coupling CKAAKN 
peptide to preformed nanoparticles. As mentioned before, the CKAAKN peptide is able to 
react with the maleimide function of the spacer via the cysteine thiol group present in its 
sequence, leading to the formation of a stable thioether bond. Noteworthy is that this site of 
derivatization does not alter the ligand/receptor recognition, as confirmed by the fact that the 
same function was used for performing the previous phage display in vivo screening.29 
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CKAAKN conjugation on preformed nanoparticles allows peptide moieties to be disposed only 
at the surface of the carriers, thus being more available for the receptor recognition. For this 
purpose, the peptide thiol group was reacted with maleimide functions of N1a 
(SQdFdC/SQMallipo molar ratio 10:1 or 5:1) using different Mal/peptide molar ratios (1:0.5 or 
1:0.25) to obtain N1a-P. Targeted NPs showed a higher mean diameter compared to untargeted 
ones (Table 1). In some cases, aggregation occurred and/or the stability was very low. The zeta 
potential value increased with the peptide amount (from -23 to -10 mV), probably due to the 
presence of two protonable amino groups in the CKAAKN moiety ((2) Figure 2). 
SQdFdC/SQMallipo/CKAAKN molar ratio 5:1:0.25 NPs (N1a-P*) showed the highest stability 
and only this nanoformulation was therefore used for further studies. The analyses of the 
amount of conjugated peptide on these NPs revealed the presence of 106866 peptide molecules 
per NP. 
The interaction between the thiol groups and maleimide functions onto N1a surface was 
investigated by isothermal titration calorimetry (ITC) analysis. This technique is widely used 
in nanotechnology for characterizing thermodynamics and stoichiometry of intermolecular 
interactions allowing the evaluation of the association constant (K), the stoichiometry, the 
enthalpy (ΔH) and the entropy (ΔS) from which the Gibbs free energy (ΔG) of the process can 
be calculated.39-41 The heat flows were determined when peptide aliquots were added to N0a 
(used as control) or N1a suspension placed in the titration cell accurately thermostated (Figure 
3a). ITC thermograms showed two different signatures: (i) a first one mainly related to the non-
specific adsorption of the peptide to the nanoparticle surface and (ii) a second one mostly 
attributed to the interaction with maleimide functions, observed only in the presence of these 
groups onto N1a. Such a hypothetical mechanism could be supported by the enthalpograms of 
the interaction between cysteine and maleimide groups in solution (Figure 3b). Whether the 
thiol-maleimide Michael addition happened on the nanoparticle surface (Figure 3b – blue line) 
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or in solution (Figure 3b – black line), the thermodynamics parameters, including the 
stoichiometry of the interaction, were comparable. Despite the maleimide group was highly 
specific for thiols, at basic pH some secondary nucleophilic additions from the amine groups 
present in the two lysines of CKAAKN sequence could also take place, 42-43 modifying the 
recognition sequence of the peptide. For this reason, we also verified that no interactions 
between lysines and the maleimide groups were established in the same conditions (Figure 3b 
– grey line). 
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Figure 3. Isothermal titration calorimetry analysis of the interaction between CKAAKN, 
cysteine (Cys) and maleimide groups. The raw and the integrated binding heats are shown in 
the upper and lower panels, respectively. Heat flows accounting for dilution effects were further 
subtracted from each experimental heat flow. a) ITC thermograms upon injection of CKAAKN 
solution into either N0a (red) or N1a (blue) suspension. b) ITC thermograms upon injection of 
(i) a Cys solution into either maleimide solution (black) or N1a suspension (blue) and (ii) 
injection of lysine into maleimide solution (grey).  
 
 
To be noted that, according to ITC results, the Michael addition reaction occurred in a larger 
extent for CKAAKN/Mal molar ratios (N) higher than 0.5. On the light of these results, it 
appeared that the CKAAKN/Mal molar ratio (1:0.25) used to formulate the N1a-P* led to the 
co-existence of both non-covalent interactions (demonstrated by ITC in other cases such as bio-
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molecular recognition or inclusion complexes 39-41) and covalent conjugation of the CKAAKN 
onto the NP surface (Figure 1b – vi). However, higher CKAAKN/Mal molar ratios could not 
be used because they led to N1a aggregation, (Table 1) likely due to peptide instability at the 
nanoparticle surface. 
 
 Preparation of targeted nanoparticles by coupling CKAAKN to SQMallipo prior to 
nanoparticle preparation. In this approach the CKAAKN peptide was previously conjugated 
to SQMallipo to give SQCKAAKN bioconjugate (5) which was then co-nanoprecipitated with 
SQdFdC at various SQdFdC/SQCKAAKN molar ratios (1:0.1, 1:0.05, 1:0.01), leading to the 
formation of peptide-functionalized NPs (N4-P). In this case only ethanol was used as organic 
solvent because of the limited solubility of SQCKAAKN in acetone. The main problem of this 
synthetic strategy is that the targeting agent could be buried in the nanoparticle core during the 
nanocarrier formation. Interestingly, the zeta potential gradually increased (from around -22 to 
+11 mV) with the increase of the percentage of SQCKAAKN in the formulations, suggesting 
the surface distribution of the peptide. As observed by DLS analysis, a SQdFdC/SQCKAAKN 
molar ratio higher than 1:0.01 led to nanoparticle destabilization and aggregation. Hence, 
SQdFdC/SQCKAAKN 1:0.01 molar ratio NPs (N4-P*), which showed a significant decrease 
of the absolute surface charge compared to untargeted NPs (N0e) (-6 vs -22 mV) and only a 
slight increase of the mean diameter, were chosen for further investigations. According to the 
hydrophilic nature of the peptide we might assume that during the nanoprecipitation process 
the CKAAKN molecules localize on the NP surface. On the basis of the SQdFdC/SQCKAAKN 
1:0.01 molar ratio used for N4-P* formulation, a value of 28385 molecules of CKAAKN per 
NP was obtained. Interestingly, N4-P* showed a marked reduction of the zeta potential value 
when increasing the pH of the medium from 7.4 to 9.8 (Figure 4). This probably resulted from 
the deprotonation of the lysine amino groups, thus supporting again the hypothesis of the 
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presence of the peptide onto the surface of the nanoparticles, which is a crucial parameter to 
obtain an efficient targeting towards cancer cells. Only a slight increase of N4-P* mean 
diameter has been observed over a period of 72 h after incubation at 37 °C in water and in cell 
culture medium containing 10% FBS (SI Figure S4).  
 
 
Figure 4. The surface charge of N0e and N4-P* as a function of pH was investigated by zeta 
potential (ZP) measurement at 25 °C after dilution with 0.02 M phosphate buffer at pH values 
ranging from 7.4 to 9.8. Values represent mean ± SD, n=3. 
 
 Surface plasmon resonance analysis. While for N4-P* the peptide was covalently 
conjugated to the nanoparticle surface, in the case of N1a-P* the ITC results suggested both 
adsorption and conjugation of the peptide on the NP surface. Covalent conjugation, in contrast 
to adsorption, ensures a stronger association between the ligand and the nanoparticles, 
especially after in vivo administration.44 However, ligand association to the nanoparticle by 
weak interactions or surface adsorption has also been proven as an alternative strategy to tailor 
targeted nanoparticles.44-45 Therefore, both coupling strategies were further investigated and the 
peptide targeting capability of N1a-P* and N4-P* was evaluated by surface plasmon resonance 
(SPR). Since it was reported that the sequence CKA-K shared motifs with the Wnt-2 protein 29, 
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sFRP-4, a secreted frizzled-related protein that binds Wnt-2, was immobilized onto the sensor 
chip surface.30, 46 The ability of the free CKAAKN peptide to specifically interact with the 
sensor chip-immobilized sFRP-4 was also verified.30 Although both N1a-P* and N4-P* were 
able to specifically interact with the receptor (which was not the case for untargeted N0e), N4-
P* enabled to reach the more important plasmonic signal after PBS washing (Figure 5).30 
 
 
Figure 5. SPR sensorgrams (resonance units (RU) versus time) obtained by simultaneous 
injections of non functionalized SQdFdC NPs (N0e) 180 µM, SQdFdC/SQMallipo/CKAAKN 
5:1:0.25 NPs (N1a-P*) 180 µM, SQdFdC/SQCKAAKN 1:0.01 NPs (N4-P*) 180 µM over 
sFRP-4 immobilized on two parallel channels of the same sensor chip.  
 
 
The enhanced target binding and specific avidity of N4-P* suggested that the peptide 
conjugation prior to nanocarrier formation was the most efficient methodology to obtain 
enhanced binding and avidity, ensuring stronger association between nanoparticles and sFRP-
4 receptor. This is of significance since earlier studies22, 47-51 have shown that the binding of a 
surface-functionalized nanoparticle to its target receptor is not only relied to the presence of the 
ligand on the nanoparticle surface. 
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 In vitro studies. In order to confirm the on the bench SPR results, the receptor targeting 
ability as a function of the synthetic strategy was evaluated in in vitro cell culture experiments. 
To this purpose, a preliminary Western Blot analysis on several cell lines was performed in 
order to assess their frizzled-5(FZD-5) receptor expression (SI Figure S2). The MIA PaCa-2 
cells were identified as high FZD-5-expressing cells and this result was further confirmed by 
immunocytochemistry (SI Figure S3). MIA PaCa-2 cells were then incubated for 6 h with 
BChol-green-labeled N0e, BChol-green-labeled N1a-P* or BChol-green-labeled N4-P*.  
 
 
 
 
 
 
 
 
 
Figure 6. a) MIA PaCa-2 cell uptake quantification of SQdFdC NPs (N0e), 
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SQdFdC/SQMallipo/CKAAKN 5:1:0.25 NPs (N1a-P*) and SQdFdC/SQCKAAKN 1:0.01 NPs 
(N4-P*) after 6-h incubation at 37 °C and 4 °C. All NPs were labeled with BChol-green and 
incubated at a final concentration of 1 µM eq. SQdFdC. b) Cell viability of MIA PaCa-2 cells 
treated with increasing concentrations of dFdC as free drug (dFdC), SQdFdC NPs (N0e), 
SQdFdC/SQMallipo/CKAAKN 5:1:0.25 NPs (N1a-P*) or SQdFdC/SQCKAAKN 1:0.01 NPs 
(N4-P*) for 72 h at 37 °C. Cytotoxicity of nanoparticles was compared to non-treated cells. 
Values represent mean ± SEM. Statistical difference N0e vs N4-P* and N1a-P* vs N4-P* 
(Student’s t-test with Bonferroni correction for multiple comparisons) is marked by ** (p < 
0.01). 
 
 
 
Although slight differences were detected after treatment with N0e and N1a-P*, remarkably the 
cell fluorescence intensity dramatically increased (by 14–fold) after N4-P* incubation (Figure 
6a). These results clearly indicated a more efficient internalization of N4-P* in comparison to 
N1a-P* in MIA PaCa-2 cells. 
When cells were incubated at 4 °C, the internalization of N4-P* dramatically decreased, 
suggesting that peptide-functionalized NPs were internalized via an energy dependent route. 
The internalization of the nanocarrier is a key issue for the drug to be efficient.52 Thus, in order 
to investigate whether the peptide functionalization enabled to achieve an increased drug 
efficacy compared to the untargeted NPs, the in vitro cytotoxicity of the different NPs and the 
free drug was investigated. As previously reported 25, all NPs were less cytotoxic than free 
dFdC due to their prodrug nature. Nevertheless, N4-P* caused a higher cytotoxicity compared 
to both N0e and N1a-P* (Figure 6b). It is worth mentioning that for N4-P* the 50% inhibition 
of cell viability (IC50) was already reached at 30 nM (eq. dFdC), while untargeted N0e were 
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not efficient in killing cancer cells in these conditions. These results clearly demonstrated the 
ability of CKAAKN-functionalized NPs not only to keep the anticancer activity of the SQdFdC, 
but also to significantly enhance the cytotoxicity. As expected, according to the ITC, SPR and 
internalization data, N1a-P* did not improve cytotoxicity in comparison to N0e treatment, thus 
suggesting the absence of specific tumor targeting ability when the peptide was mainly 
adsorbed at the NP surface. 
To further investigate the ability of N4-P* to specifically target cancer cells, the interaction 
with NIH/3T3, a non cancerous fibroblastic cell line, was studied and compared to the uptake 
by MIA PaCa-2 cancer cells. Western blot analysis showed that NIH/3T3 healthy cells 
displayed a low expression of FZD-5 receptor (Supporting Information S2). As shown in Figure 
7, non-functionalized nanoparticles (N0e) were taken-up mainly by NIH/3T3 fibroblasts in a 
nonspecific manner, resulting in higher accumulation in this cell line. On the contrary, N4-P* 
were internalized into MIA PaCa-2 cells by a receptor-mediated mechanism, which allowed 
nanoparticles achieving highly selective tumor cell uptake and toxicity, while decreasing non-
specific accumulation into healthy cells (Figure 7a). As shown by fluorescence quantification 
studies after 6 h, the peptide-functionalization caused a 6-fold decrease of nanoparticles uptake 
by healthy NIH/3T3 cells compared to MIA Paca-2 cells (Figure 7b). Cytotoxicity studies 
clearly demonstrated that peptide functionalization was able to selectively increase cytoxicity 
toward MIA PaCa-2 pancreatic cancer cells. Indeed, the same concentration of N4-P* (i.e, 30 
nM eq. dFdC) responsible of the 50% reduction of cell viability on malignant MIA PaCa-2 cells 
maintained more than 93% of viable healthy NIH/3T3 cells (Figure 7a). Of note, non 
functionalized NPs were not efficient in killing cancer cells, since 100% cell viability was still 
observed after incubation at the same concentration. The higher uptake of N0e by NIH/3T3 
fibroblasts was not accompanied by important cytotoxicity, as consequence of a lower 
sensitivity of this cell line to gemcitabine at the tested doses, as already reported in literature53-
20 µm 
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54. The selective capture of functionalized NPs by cancer cells was further confirmed in a 
coculture experiment of healthy NIH/3T3 cells (stained in green) and MIA PaCa-2 cells 
(unstained) incubated with red fluorescently-labeled nanoparticles (Figure 7c,d). Confocal 
images clearly showed similar uptake of non-functionalized NPs in both tumor and healthy cells 
(Figure 7c), whereas N4-P* were selectively captured by tumor cells and healthy cells were 
saved from nanoparticles recognition (Figure 7d). 
 
 
 
 
Figure 7. (a) Viability of NIH/3T3 and MIA Paca-2 cells treated for 72 h with SQdFdC NPs 
(N0e) and SQdFdC/SQCKAAKN NPs (N4-P*) (30 nM eq. dFdC). Values represent mean ± 
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SEM. (b) Quantification of cellular uptake of BChol-green-labeled SQdFdC NPs (N0e) and 
BChol-green-labeled SQdFdC/SQCKAAKN NPs (N4-P*) in NIH/3T3 and MIA PaCa-2 cells 
at 37 °C. Values represent mean ± SEM. (c) Confocal laser-scanning microscopy images of a 
coculture of NIH/3T3 (green) and MIA PaCa-2 cells (unstained) after incubation with BChol-
red-labeled SQdFdC NPs (N0e) and (d) BChol-red-labeled SQdFdC/SQCKAAKN NPs (N4-
P*). Scale bar = 20 µm.  
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CONCLUSIONS 
This study demonstrates that the best strategy to prepare CKAAKN-functionalized SQdFdC 
NPs relies in the conjugation of the peptide to the SQMallipo derivative prior nanoparticle 
formation. Taken together, our results clearly highlight that actively targeted nanoparticles 
should not be simply designed as single modular assemblies of scaffold, linker and targeting 
ligand, but rigorous studies must be performed in order to clarify how different structural 
components collaborate to reach the most efficient cell targeting ability. In a nutshell, the 
successful functionalization of SQdFdC nanoparticles makes this system a good example to 
highlight the subtle equilibrium which governs the design of actively targeted NPs able to 
effectively improve anticancer activity. 
 
EXPERIMENTAL PROCEDURES 
 Chemicals. Gemcitabine (2’,2’-difluorodeoxycitidine, dFdC) hydrochloride was 
purchased from Sequoia Research Products Ltd. (Pangbourne, UK). CKAAKN peptide was 
purchased from CASLO Laboratory Aps (Lyngby, Denmark). Squalene, dextrose, maleimide 
and all other reagents were obtained by Sigma-Aldrich Chemical Co. (Milan, Italy). Squalene 
derivatives (Figure 2) (4-(N)-trisnorsqualenoylgemcitabine (SQdFdC) (1)23, 6-
(maleimidocaproyl)hydrazone of squalene (SQMallipo) (3)30, 2-[2-(2,5-dioxo-2,5-dihydro-1H-
pyrrol-1-yl)ethoxy]ethyl (4E,8E,12E,16E)-4,8,13,17,21-pentamethyl-docosa-4,8,12,16,20-
pentaenoate (SQMalhydro) (4)31) were obtained as previously reported. All solvents were of 
analytical grade from Carlo Erba Reagenti (Milan, Italy) or VWR (Fontenay-sous-Bois, 
France).  
 Preparation and characterization of non targeted nanoparticles. SQdFdC, 
SQdFdC/SQMallipo, SQdFdC/SQMalhydro and SQMallipo nanoparticles (NPs) were prepared by 
nanoprecipitation.23, 55 (Table 1) Practically, for SQdFdC NPs (N0), 2 mg of SQdFdC were 
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dissolved in acetone (N0a) or ethanol (N0e); the organic solution was then added dropwise 
under magnetic stirring into MilliQ® water (solvent/water 1:2 v/v). Formation of the 
nanoparticles occurred spontaneously without using any surfactant. After solvent evaporation 
under reduced pressure, an aqueous suspension of nanoparticles was obtained (final SQdFdC 
concentration: 2 mg/mL). 
For SQdFdC/SQMallipo NPs (N1), SQdFdC and SQMallipo were co-dissolved in acetone (N1a) 
or ethanol (N1e) in various SQdFdC/SQMallipo molar ratios (10:1 (2 mg of SQdFdC and 0.183 
mg of SQMallipo), 5:1 (2 mg of SQdFdC and 0.366 mg of SQMallipo) and 2:1 (2 mg of SQdFdC 
and 0.915 mg of SQMallipo)). The organic solution was then added dropwise under magnetic 
stirring into MilliQ® water (solvent/water 1:2 v/v). Formation of the nanoparticles occurred 
spontaneously without using any surfactant. After solvent evaporation under reduced pressure, 
an aqueous suspension of nanoparticles was obtained (final SQdFdC concentration: 2 mg/mL).  
For SQdFdC/SQMalhydro NPs (N2), SQdFdC and SQMalhydro were co-dissolved in ethanol in 
various molar ratios (10:1 (2 mg of SQdFdC and 0.164 mg of SQMalhydro) and 5:1 (2 mg of 
SQdFdC and 0.328 mg of SQMalhydro)). The organic solution was then added dropwise under 
magnetic stirring into MilliQ® water (ethanol/water 1:2 v/v). Formation of the nanoparticles 
occurred spontaneously without using any surfactant. After solvent evaporation under reduced 
pressure, an aqueous suspension of nanoparticles was obtained (final SQdFdC concentration: 2 
mg/mL). 
For SQMallipo NPs (N3), 2 mg of SQMallipo were dissolved in acetone at various concentrations. 
After the addition of the organic solution to MilliQ® water (acetone/water 1:2 v/v) and solvent 
evaporation, an aqueous suspension of nanoparticles was obtained (SQMallipo concentration: 
0.5, 1 or 2 mg/mL).  
Fluorescently-labeled SQdFdC NPs and fluorescently-labeled SQdFdC/SQMallipo NPs were 
obtained using the same procedure, unless 1% (w/w) of the fluorescent probe CholEsteryl 
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BODIPY® FL C12 (BChol-green) or CholEsteryl BODIPY® 542/563 C11 (Life Technologies, 
Molecular Probes, Saint Aubin, France) was dissolved in the ethanolic solution before dropwise 
addition into water. 
The mean particle size and the polydispersity index of all formulations were measured by 
dynamic light scattering (DLS) with a Nano ZS from Malvern (UK) (173° scattering angle) at 
25 °C. The measurements were performed after dilution of the NP suspensions (1/25 v/v) in 
MilliQ® water. The NP surface charge was investigated by zeta potential measurements at 25 
°C after dilution with 0.05 mM KCl solution applying the Smoluchowski equation and using 
the same apparatus. Measurements were carried out in triplicate. The colloidal stability of the 
formulations was evaluated by measuring the size and the zeta potential of the nanoparticles 
over a storage period of 7 days at 4 °C.  
 Preparation and characterization of targeted nanoparticles by coupling CKAAKN 
peptide to preformed nanoparticles. CKAAKN stock solution (100X) was prepared by 
dissolving the peptide in 1 mM freshly degased phosphate buffer at pH 8.2. To obtain 
CKAAKN-conjugated SQdFdC/SQMallipo NPs (N1-P), 100 µL of N1a were added dropwise 
under gentle magnetic stirring to 1 mL of CKAAKN working solution (1X) in various molar 
ratios (SQdFdC/SQMallipo/CKAAKN molar ratio 10:1:0.5 (0.2 mg of SQdFdC, 0.0183 mg of 
SQMallipo and 0.0098 mg of CKAAKN) or 10:1:0.25 (0.2 mg of SQdFdC, 0.0183 mg of 
SQMallipo and 0.0049 mg of CKAAKN) or 5:1:0.5 (0.2 mg of SQdFdC, 0.036 mg of SQMallipo 
and 0.0196 mg of CKAAKN) or 5:1:0.25 (0.2 mg of SQdFdC, 0.036 mg of SQMallipo and 
0.0098 mg of CKAAKN); final SQdFdC concentration: 0.18 mg/mL) (Table 1). The reaction 
was carried out for 1 h at room temperature under stirring. The CKAAKN-functionalized 
nanoparticles (N1a-P) were then purified from unreacted peptide by centrifugal filter units (30 
kDa) at 14000 g for 1 minute (Amicon Ultra-0.5, Millipore). The mean size, the polydispersity 
index and the zeta potential of purified N1a-P were determined at 25 °C by DLS as described 
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above. The stability of the formulations was evaluated by measuring the size and the zeta 
potential of the nanoparticles over a storage period of 7 days at 4 °C. The amount of peptide 
molecules at the surface of the NPs has been evaluated by: i) titration of unreacted peptide in 
an unpurified aliquot of conjugated nanoassemblies by reaction with the Ellman’s reagent (5,5’‐
dithio‐bis‐(2‐nitrobenzoic acid), DTNB) by quantitative UV spectrophotometric analysis 
(absorbance at 412 nm)56 ; ii) a retro-titration of the available maleimide groups present on the 
nanoparticle surface by quantitative fluorimetric analysis (Maleimide Quantification Assay Kit 
(Fluorometric) Abcam, ab112141) according to manufacturer’s instructions. 
 Isothermal titration calorimetry (ITC) analysis of N1a nanoparticles. The 
interaction between the maleimide (Mal) function and the CKAAKN peptide was investigated 
by isothermal titration calorimetry. The ITC instrument (VP-ITC, MicroCal, GE Healthcare 
Life Sciences, Velizy-Villacoublay, France) was periodically calibrated either electrically, 
using an internal electric heater, or chemically by measuring the dilution enthalpy of methanol 
in water. This standard reaction was in excellent agreement (1-2%) with the MicroCal 
constructor data.57-58 In a typical experiment, aliquots of 10 μL of CKAAKN peptide, cysteine 
(Cys) or lysine in 0.03 M phosphate buffer solution at pH 8.2 (3.1 mM eq. Cys or 12.4 mM eq. 
lysine) filled into 283 μL syringe were used to titrate a suspension of either N1a or maleimide 
in 0.03 M phosphate buffer solution at pH 8.2 (0.31 mM eq. Mal) into the calorimetric cell 
accurately thermostated at 25 °C. The corresponding heat flows were recorded as a function of 
time. Intervals between injections were 600 s and agitation speed was 220 rpm. Control 
experiments with N0a into the calorimetric cell were carried out using the equivalent total 
squalene amount present in N1a. Background of titration consisted on injecting the CKAAKN 
peptide or Cys in solely phosphate buffer solution placed in the sample cell.  
The interaction process was analyzed by employing the models proposed in the Windows-based 
Origin 7 software package supplied by MicroCal. Based on the concentrations of the two 
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species, the software used a nonlinear least-squares algorithm to fit the series of heat flows to 
an equilibrium binding equation, providing the best-fit values of the stoichiometry, binding 
constant (K) and change in enthalpy (ΔH). From these results, the differences in free energy 
(ΔG) and the entropy (ΔS) were deducted according to the equation:  
 ΔG = - RT ln K = ΔH – TΔS 
 Preparation of targeted nanoparticles by coupling CKAAKN to SQMallipo prior to 
nanoparticle preparation. To obtain SQdFdC/SQCKAAKN nanoparticles (N4-P), CKAAKN 
peptide was first conjugated to SQMallipo to give SQCKAAKN (5) (SI Figure S1). To obtain 
SQMallipo (3), a solution of 1,1’,2-trisnorsqualenic aldehyde (8) (0.334 g, 0.868 mmol) in 
CH2Cl2 was added to dry methanol (15 mL). The resulting mixture was sonicated few minutes 
until complete dissolution. [6-(maleimido)hexanamido]azanium trifluoroacetate (7) (0.306 g, 
0.868 mmol) and 4 Å molecular sieves (200 mg) were then added and the reaction mixture was 
stirred for 1 h at room temperature under nitrogen. The formation of the desired product (3) was 
monitored by TLC (petroleum ether/ethyl acetate 1/1 v/v, Rf: 0.65). The mixture was filtered 
and concentrated under reduced pressure. The residue was taken into water (5 mL) and 
extracted with CH2Cl2 (3 x 15 mL). The combined organic phases were dried over anhydrous 
MgSO4 and concentrated in vacuo. Purification by flash-chromatography on silica column, 
eluting with a gradient of petroleum ether to petroleum ether/ethyl acetate 60/40 v/v, gave the 
product as a light yellow waxy material (0.211 g, 63% yield) (SI Figure S1). 
1H NMR (CDCl3) δ: 8.39 (s, 1H, CH=NN), 7.05 (t, J = 5.2 Hz, 1H, NHCO), 6.68 (s, 2H, CO-
CH=CHCO), 5.14‐5.07 (m, 5H, HC=C(CH3)), 3.54‐3.49 (t, J = 7.2 Hz, 2H, CH2N), 2.70-2.50 
(m, 2H, CH2CONH), 2.40‐1.90 (m, 20H, =C(CH3)CH2CH2), 1.80 (s, 3H, HC=C(CH3)2), 1.76‐
1.65 (m, 12H, HC=C(CH3)CH2), 1.62‐1.60 (m, 4H, NCH2CH2CH2CH2CH2CON), 1.41‐1.33 
(m, 2H, NCH2CH2CH2CH2CH2CON). 13C NMR (CDCl3) δ: 171.2, 166.3, 147.3, 135.8, 135.7‐
132.0, 125.9‐124.7, 42.5, 39.7‐26.4, 38.2, 36.6, 31.0, 26.9, 25.9, 24.6‐16.4, 22.4. MS (EI): 
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m/z(%) 81 (70), 110 (100), 192 (55), 591 (3). HPLC analysis: Symmetry C18 column, 5 µm 
(Merck, Italy) equipped with a C18 column guard, elution with 100% methanol, detection by 
UV adsorption measurement at 237 nm (flow rate 1 mL/min, tr=5.79 min). Peak heights were 
recorded and processed on a CBM-10A Shimadzu interface. 
To synthesize the Michael adduct of CKAAKN (2) and 6-(maleimidyl)-hexanoic acid 
(trisnorsqualenylidene)-hydrazide (3) (SQCKAAKN, (5)), a mixture of SQMallipo (3) (13.5 mg, 
0.0229 mmol) and CKAAKN peptide (2) (7.25 mg, 0.0114 mmol) in dimethylformamide 
(DMF)/H2O 3/1 v/v (2 mL) was stirred for 3 h at 40 °C. The reaction mixture was then 
concentrated under reduced pressure and the crude product was taken into diethyl ether to 
remove unreacted maleimide derivative. The supernatant was withdrawn after decantation (3 
times). In order to eliminate unreacted peptide, the solid was dissolved in methanol and filtered 
through a sintered glass funnel. The product was obtained as a translucent waxy material (10 
mg, 0.0082 mmol, 70% yield).30 (SI Figure S1). 
1H NMR (CD3OD, 400 MHz) due to the presence of a 7:3 E/Z mixture at the hydrazone bond 
and to the asymmetric center on the maleimide moiety some signals are split, δ : 7.43 (t, J = 5.4 
Hz, 0.7H, CH=NNHCO), 7.28 (m, 0.3H, CH=NNHCO), 5.20 (t, J = 6.6 Hz, 1H, HC=C(CH3)), 
5.15-5.06 (m, 4H, HC=C(CH3)), 4.71 (t, J = 5.6 Hz, 1H, NOCCH(CH2CONH2)NH), 4.42-4.25 
(m, 5H, NOCCH(CH3)NH, NOCCH(CH2CH2CH2CH2NH3)NH, NOCCH(CH2S)NH2,), 
3.70-3.60 (m, 1H, CH2S(CHCH2CONCO), 3.52 (t, J = 7.0 Hz, 2H, CH2N-maleimide), 3.50-
3.43 (m, 1H, CH2SCHCH2CO), 3.30-3.10 (m, 3H, CH2S(CHCH2CONCO), 
CH2S(CHCH2CONCO), 3.02-2.92 (m, 4H, CH2CH2CH2CH2NH3), 2.83 (dd, J = 16.0 Hz, J = 
6.4 Hz, 1H, NOCCH(CH2CONH2)NH), 2.76 (dd, J = 16.0 Hz, J = 4.8 Hz, 1H, 
NOCCH(CH2CONH2)NH), 2.62-2.30 (m, 4H, CH2CH2CON, CH2CH2C=NNH), 2.25-2.15 
(m, 4H, CH2CH2NH3), 2.17-1.85 (m, 22H, =C(CH3)CH2CH2, 
NOCCH(CH2CH2CH2CH2NH3)NH), 1.75-1.65 (m, 4H, 
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NOCCH(CH2CH2CH2CH2NH3)NH), 1.67 (s, 3H, =C(CH3)2), 1.64 (s, 3H, 
=C(CH3)CH2CH2), 1.60 (s, 12H, =C(CH3)CH2CH2), 1.60-1.45 (m, 4H, 
=NHNCOCH2CH2CH2CH2CH2N-maleimide), 1.40 (d, J = 7.2 Hz, 6H, COCH(CH3)NH), 
HNCOCH2CH2CH2CH2CH2N-maleimide); MS (+ESI), m/z (%), 1226.0 (100) [M+H]+, 614.5 
(3) [M+2H]2+; HRMS (+ESI) calcd for C62H105N12O5S: 1225.7741; found 1225.7690. 
Nanoparticles were then prepared by nanoprecipitation. Practically, SQdFdC and SQCKAAKN 
were dissolved in 0.1 mL of ethanol in various molar ratios (SQdFdC/SQCKAAKN 1:0.1 (3.42 
mg of SQdFdC and 0.64 mg of SQCKAAKN), 1:0.05 (3.42 mg of SQdFdC and 0.32 mg of 
SQCKAAKN) and 1:0.01 (3.42 mg of SQdFdC and 0.064 mg of SQCKAAKN)) and this 
organic solution was then added dropwise under magnetic stirring into 1 mL of MilliQ® water 
(ethanol/water 0.1:1 v/v). After solvent evaporation under reduced pressure, an aqueous 
suspension of nanoparticles (N4-P) was obtained (final SQdFdC concentration: 3.4 mg/mL) 
(Table 1). The mean size and the polydispersity index of the formulations were determined as 
described above. The NP surface charge was investigated by zeta potential measurements at 25 
°C after dilution with 0.05 mM KCl solution or 0.02 M phosphate buffer at pH values ranging 
from 7.4 to 9.8, applying the Smoluchowski equation and using the same apparatus. 
Fluorescently-labeled nanoparticles were prepared as described above. The stability of N4-P* 
has been investigated over a period of 72 h after incubation at 37 °C in water and in cell culture 
medium containing 10% FBS. 
 Surface plasmon resonance (SPR) analysis. Interaction analyses were performed on 
a BIAcore T100 instrument using CM5 Series S sensor chip from GE Healthcare Life Sciences 
Europe. The activation of the carboxymethylated dextran matrix was performed with a mixture 
of 0.1 M N-ethyl-N’-(3-diethylaminopropyl)-carbodiimide (EDC) / 0.4 M N-
hydroxysuccinimide (NHS) (1:1 v/v) (GE Healthcare) for 7 min. Running buffer for the 
immobilization process was 150 mM phosphate buffer, pH 7.4 at a flow rate of 10 µL/min. The 
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sFRP-4 receptor was then injected over the activated surface at 10 µg/mL in 10 mM sodium 
acetate buffer at pH 4.4 during 7 min, giving an average immobilization level of 2800 resonance 
units (RU). A solution of 1 M ethanolamine hydrochloride at pH 8.5 was then injected during 
7 min to block the unreacted sites of the matrix. For reference, an additional blank flow channel 
was prepared in accordance with the same process without injecting the receptor over the 
surface. Binding capacities of the functional surfaces were tested with 180 s-injections of a 
peptide solution, N0e, N1a-P* (SQdFdC/SQMal/CKAAKN molar ratio 5:1:0.25) or N4-P* 
(SQdFdC/SQCKAAKN molar ratio 1:0.01) at different concentrations. All experiments were 
carried out in duplicate at 25 °C in Dulbecco-PBS (D-PBS) running buffer on the InterMol-
IPSIT platform (Châtenay-Malabry, France). 
 Cell culture. Human pancreatic carcinoma cell lines MIA PaCa-2, BxPC3, PANC-1, 
breast cancer cell line MCF-7 and embryonic murine fibroblasts NIH/3T3 were obtained from 
the American Type Culture Collection (Molsheim, France) and maintained as recommended. 
Briefly, MIA PaCa-2, PANC-1, MCF-7 and NIH/3T3 cells were grown in Dulbecco's Modified 
Eagle Medium (DMEM) supplemented with 10% heat-inactivated (56 °C, 30 min) fetal bovine 
serum (FBS). In addition, MIA Paca-2 cell medium was supplemented with 2.5% heat-
inactivated horse serum (Gibco, Saint Aubin, France). BxPC3 cells were maintained in Roswell 
Park Memorial Institute medium (RPMI 1640 Lonza, Braine-l’Alleud, Belgium) supplemented 
with 10% heat-inactivated FBS. All media were further supplemented with 50 U.mL-1 penicillin 
and 50 U.mL-1 streptomycin (Lonza, Levallois, France). Cells were maintained in a humid 
atmosphere at 37 °C with 5% CO2. Cells were used between passage 3 and 12 after thawing. 
 Western Blot. Pancreatic adenocarcinoma (BxPC3, MIA PaCa-2, PANC-1), breast 
cancer (MCF-7) and embryonic fibroblast cells (NIH/3T3) were lysed in RIPA buffer (Sigma-
Aldrich) supplemented with PierceTM phosphatase and protease inhibitor cocktail (Thermo 
Fisher Scientific, Perbio Science, Brebières, France), vortexed and then centrifuged for 5 min 
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at 3000 g. The protein concentration in the supernatant was then measured using a colorimetric 
assay (Bio-Rad Protein Assay Dye, Bio-Rad Laboratories, Marnes-la-Coquette, France). Equal 
amount of proteins (30 µg) were boiled for 10 min with the same volume of Laemmli Sample 
Buffer (Bio-Rad Laboratories, Marnes-la-Coquette, France), supplemented with 5% beta-
mercaptoethanol and then separated in sodium dodecylsulphate (SDS)-polyacrylamide gels 
(Mini-Protean - TGX 4-15% - Precast Gels Bio-Rad) and electrically transferred to 
polyvinylidene difluoride (PVDF) membrane using a semi-dry transfer system (20 V, 1 h). The 
membrane was blocked with 5% dry milk suspension in 0.1% Tween 20 in PBS (blocking 
buffer), then incubated for 2 h at room temperature with the primary antibody solution in 
blocking buffer and, after 30 min washing in PBS-Tween 20 0.1% buffer, incubated for 1 h at 
room temperature with the secondary antibody solution in blocking buffer. Antibodies were 
used at the following dilutions: polyclonal rabbit anti-FZD-5 diluted 1/1000 (Millipore), mouse 
anti-β-actin diluted 1/3000 (Sigma-Aldrich), goat anti-mouse secondary antibody conjugated to 
horse radish-peroxydase diluted 1/2000 (SantaCruz Biotechnology, Clinisciences, Nanterre, 
France) and goat anti-rabbit secondary antibody conjugated to horse radish-peroxydase diluted 
1/5000 (SantaCruz Biotechnology, Clinisciences). Detection of chemiluminescence was 
performed using the ClarityTM Western ECL substrate (Bio-Rad Laboratories) and images were 
captured by the ChemiBIS system from DNR Bioimaging Systems (Thoiry, France). MCF-7 
cell line was used as a positive control.59 
 Immunocytochemistry. MIA PaCa-2 cells (2.5 x 104 cells/mL) were plated in growing 
medium onto microscopic glass slides in 24-well plate and incubated for 24 h at 37 °C with 5% 
CO2. Nuclei were stained with 10 µM Syto Red Fluorescent dye (SYTO61 - S11343, Life 
Technologies, Molecular Probes, Saint Aubin, France) according to the manufacturer’s 
protocol. After staining, cells were fixed with 4% paraformaldehyde in PBS, incubated for 30 
min at room temperature in blocking solution (1% bovine serum albumin, 0.3 M glycine, 0.1% 
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Tween 20 in PBS) and then with the polyclonal rabbit anti-FZD-5 diluted 1/500 (Abcam, UK) 
for 1 h. Then, the cells were washed with PBS-Tween 20 0.1% for 30 min and stained for 1 h 
at room temperature in dark with an Alexa Fuor®555-conjugated secondary antibody diluted 
1/500 (Abcam, UK). Cells were then rinsed three times with PBS and analyzed by confocal 
laser scanning microscopy. Cells incubated with the Alexa Fuor®555-conjugated secondary 
antibody diluted 1/500 only were used as negative control. 
 Cell internalization of NPs. MIA PaCa-2 or NIH/3T3 cells (5 x 104 cells/mL) were 
cultured in 12-well plates for 24 h to achieve approximately 40% confluence. Cells were then 
incubated at 37 °C with 5% CO2 for 6 h with 1 µM of freshly prepared BChol-green-labeled 
SQdFdC NPs (N0e), SQdFdC/SQMallipo/CKAAKN 5:1:0.25 NPs (N1a-P*) or 
SQdFdC/SQCKAAKN 1:0.01 NPs (N4-P*). Free BChol-green was used as control. After 
treatment, supernatants were discarded, cells rinsed twice with PBS and harvested for 
measurement. Cell suspensions were analyzed by flow cytometry (Accuri C6, BD Biosciences, 
Le Pont de Claix, France) and mean fluorescence intensities were collected between 515 and 
545 nm, using the 488-nm line of an argon laser for excitation. For all experiments 10000 cells 
were measured from each sample. 
For low temperature experiments, the cells were incubated in the cold room at 4 °C for 5 h. 
Results were expressed as the ratio of the mean fluorescence intensity of each sample to the 
mean fluorescence intensity of non treated cells. This value was then corrected by the 
fluorescence factor of each NP suspension. All measurements were performed in triplicate or 
more to determine means and SD. 
 Cytotoxicity studies. The in vitro cytotoxicity of NPs was investigated on MIA PaCA-
2 and NIH/3T3 cell lines through the determination of the mitochondrial activity, using the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide test (MTT, Sigma-Aldrich). 
Briefly, cells were seeded in 100 µL of growth medium (MIA PaCa-2 (1 x 104 cells/mL), 
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NIH/3T3 (0.75 x 104 cells/mL)) in 96-well plates and preincubated for 24 h. Cells were then 
treated with 100 µL of a series of concentrations of different nanoparticle suspensions for 72 h. 
Initial cell density and incubation time were determined to allow cells to remain in exponential 
growth and to undergo two cell-doubling times during the assay. At the end of the incubation 
period, 20 µL of a 5 mg/mL MTT solution in phosphate buffered saline were added to each 
well. After 2 h of incubation, the culture medium was removed and replaced by 200 µL of 
dimethyl sulfoxide (DMSO), in order to dissolve the formazan crystals. The absorbance of the 
solubilized dye was measured spectrophotometrically with a microplate reader (LAB System 
Original Multiscan MS) at 570 nm. The percentage of viable cells for each treatment was 
calculated from the ratio of the absorbance of the well containing the treated cells versus the 
average absorbance of the control wells (i.e., untreated cells). All experiments were set up in 
triplicate.  
Coculture. NIH/3T3 fibroblasts (7.5 x 104 cells) were plated onto microscopic glass slides and 
incubated for 18 h at 37 °C with 5% CO2 in complete medium. To visualize and distinguish 
between NIH/3T3 fibroblasts and MIA PaCa-2 cells in coculture, NIH/3T3 cells were stained 
with 5 μM CellTracker green 5-chloromethylfluorescein diacetate (CMFDA, Life Technology, 
Molecular Probes) according to the manufacturer's protocol. After staining, cells were left to 
rest for 2 h at 37 °C with 5% CO2 in cell culture medium, and then unstained MIA PaCa-2 cells 
(15 x 104 cells) were co-incubated. The seeding ratio between MIA PaCa-2 and NIH/3T3 cells 
was 2:1 due to the faster doubling time of the latter. After 18 h, the coculture was incubated 
with BChol-red-labeled SQdFdC NPs and BChol-red-labeled SQdFdC/SQCKAAKN NPs 
diluted in fresh cell culture medium at 10 μM. At different time points (2, 6, and 24 h) 
nanoparticles were withdrawn and cells washed with pre-warmed culture medium before 
imaging. Free BChol-red was used as control. 
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Confocal laser scanning microscopy. Observations were made by sequential acquisition with 
a Zeiss LSM-510 confocal laser microscope equipped with a 1 mW argon laser and 1 mW 
helium neon laser, using a Plan-Apochromat 20X or 63X objective lens (NA 1.40, oil 
immersion). Green fluorescence (CMFDA) was observed with a band-pass 505 and 550 nm 
emission filter and under a 488 nm laser illumination. Red fluorescence (BChol-red) was 
observed with a long-pass 560 nm emission filter and under a 543 nm laser illumination. The 
pinhole diameter was set at 98 μm for CMFDA and 106 μm for BChol-red and an optical section 
thickness of 0.4 μm was fixed. Twelve bit numerical images were acquired with Carlo Zeiss 
ZEN 2011 software version 7.1. 
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ABBREVIATIONS 
dFdC, Gemcitabine; DLS, Dynamic light scattering; DMEM, Dulbecco's modified eagle 
medium; EDC, N-ethyl-N’-(3-diethylaminopropyl)-carbodiimide; ESI, electron spray 
ionization; FBS, Fetal bovine serum; FZD, Frizzled; IC50, half maximal inhibitory 
concentration; ITC, Isothermal titration calorimetry; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide; NP, Nanoparticle; NHS, N-hydroxysuccinimide; N0a, SQdFdC 
nanoparticles, acetone as organic solvent; N0e, SQdFdC nanoparticles, ethanol as organic 
solvent; N1, SQdFdC/SQMallipo nanoparticles; N1a, SQdFdC/SQMallipo nanoparticles, acetone 
as organic solvent; N1e, SQdFdC/SQMallipo nanoparticles, ethanol as organic solvent; N2, 
SQdFdC/SQMalhydro nanoparticles; N3, SQMallipo nanoparticles; N4-P, 
SQdFdC/SQCKAAKN nanoparticles; PDI, Polydispersity index; SD, standard deviation; SEM, 
standard error of the mean; SPR, Surface plasmon resonance; SQ, Squalene; SQdFdC, 4-(N)-
1,1’,2-Trisnorsqualenoylgemcitabine/4-(N)-1,1’,2-trisnorsqualenoyl-2’,2’-difluoro-2’-
deoxycytidine; SQdFdC/SQCKAAKN NPs, CKAAKN-functionalized squalenoylgemcitabine 
nanoparticles; SQCKAAKN, Michael adduct of CKAAKN and 6-(2,5-dioxo-2,5-dihydro-1H-
38 
 
pyrrol-1-yl)-N'-[(4E,8E,12E,16E)-4,8,13,17,21-pentamethyldocosa-4,8,12,16,20-pentaen-1-
ylidene]hexanehydrazide; SQMalhydro, 2-[2-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-
yl)ethoxy]ethyl (4E,8E,12E,16E)-4,8,13,17,21-pentamethyldocosa-4,8,12,16,20-pentaenoate; 
SQMallipo, 6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)-N'-[(4E,8E,12E,16E)-4,8,13,17,21-
pentamethyldocosa-4,8,12,16,20-pentaen-1-ylidene]hexanehydrazide; ZP, Zeta potential. 
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